Bristol-Myers Squibb Latest To License DPP-4 Patents From OSI
This article was originally published in The Pink Sheet Daily
Executive Summary
OSI "owns the patent estate" on DPP-4 inhibitors and has licensed the medical use patents to Merck, Novartis and others.
You may also be interested in...
OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Goddard talks about OSI’s metabolic syndrome pipeline, competing with Merck in the DPP-4 space and profitability.
OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Goddard talks about OSI’s metabolic syndrome pipeline, competing with Merck in the DPP-4 space and profitability.
Lilly Licenses OSI Glucokinase Activator Program For Type 2 Diabetes
The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.